The global roadmap for advancing development of vaccines against sexually transmitted infections: Update and next steps  by Gottlieb, Sami L. et al.
T
s
S
C
C
a
b
c
d
e
f
B
g
h
i
a
A
A
K
S
V
S
R
1
m
o
i
a
o
a
b
d
m
i
W
h
0Vaccine 34 (2016) 2939–2947
Contents lists available at ScienceDirect
Vaccine
j our na l ho me page: www.elsev ier .com/ locate /vacc ine
he  global  roadmap  for  advancing  development  of  vaccines  against
exually  transmitted  infections:  Update  and  next  steps
ami  L.  Gottlieba,∗,  Carolyn  D.  Dealb, Birgitte  Giersinga, Helen  Reesc,  Gail  Boland,
hristine  Johnstone, Peter  Timmsf, Scott  D.  Gray-Oweng, Ann  E.  Jerseh,
aroline  E.  Cameroni,  Vasee  S.  Moorthya, James  Kiariea, Nathalie  Brouteta
World Health Organization, Geneva, Switzerland
National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
Wits Reproductive Health and HIV Institute, University of the Witswatersrand, Johannesburg, South Africa
Centers for Disease Control and Prevention, Atlanta, GA, USA
University of Washington, Seattle, WA,  USA
University of Sunshine Coast, Queensland Australia and Institute of Health and Biomedical Innovation, Queensland University of Technology,
risbane, Australia
University of Toronto, Toronto, ON, Canada
Uniformed Services University, Bethesda, MD, USA
University of Victoria, Victoria, BC, Canada
 r  t  i  c  l  e  i  n  f  o
rticle history:
vailable online 19 April 2016
eywords:
exually transmitted infections
a  b  s  t  r  a  c  t
In 2014,  the World  Health  Organization,  the  US  National  Institutes  of Health,  and  global  technical  part-
ners  published  a comprehensive  roadmap  for development  of  new  vaccines  against  sexually  transmitted
infections  (STIs).  Since  its publication,  progress  has  been  made  in  several  roadmap  activities:  obtaining
better  epidemiologic  data  to establish  the public  health  rationale  for STI  vaccines,  modeling  the  theoreticalaccines
TI vaccine development
oadmap
impact  of  future  vaccines,  advancing  basic  science  research,  deﬁning  preferred  product  characteristics  for
ﬁrst-generation  vaccines,  and  encouraging  investment  in STI  vaccine  development.  This  article  reviews
these  overarching  roadmap  activities,  provides  updates  on  research  and  development  of individual  vac-
cines against  herpes  simplex  virus,  Chlamydia  trachomatis,  Neisseria  gonorrhoeae,  and Treponema  pallidum,
and  discusses  important  next  steps  to  advance  the global  roadmap  for  STI  vaccine  development.
 Orga©  2016  World  Health
. Introduction
Vaccines against sexually transmitted infections (STIs) are a
ajor priority for sustainable global STI control. Development
f new STI vaccines is critical because of the large number of
nfections worldwide, the resulting adverse sexual, reproductive
nd maternal-child health outcomes, and important limitations
f existing STI interventions. Safe and highly efﬁcacious vaccines
gainst human papillomavirus (HPV) and hepatitis B virus have
een major advances in STI prevention and provide inspiration for
evelopment of new STI vaccines.The World Health Organization (WHO) estimates that 357
illion new cases of curable STIs occurred in 2012 worldwide,
ncluding Chlamydia trachomatis (chlamydia), Neisseria gonorrhoeae
∗ Corresponding author at: Department of Reproductive Health and Research,
HO, Avenue Appia 20, CH-1211 Geneva 27, Switzerland. Tel.: +41 22 791 34 24.
E-mail address: gottliebs@who.int (S.L. Gottlieb).
ttp://dx.doi.org/10.1016/j.vaccine.2016.03.111
264-410X/© 2016 World Health Organization; licensee Elsevier Ltd. This is an open accenization;  licensee  Elsevier  Ltd. This  is  an  open  access  article  under  the  CC
BY  license  (http://creativecommons.org/licenses/by/3.0/).
(gonorrhea), Treponema pallidum (syphilis), and Trichomonas vagi-
nalis (trichomoniasis) infections [1]. STI numbers were high
across all world regions (Fig. 1). In addition, prevalent her-
pes simplex virus type 2 (HSV-2) infection, the main cause
of genital herpes, affected an estimated 417 million people
globally in 2012 (Fig. 2) [2], and more than 100 million addi-
tional people were estimated to have genital infection with
HSV-1 [3].
STIs can result in a number of adverse outcomes. Mother-
to-child transmission of syphilis leads to over 300,000 fetal and
neonatal deaths per year [4]. HPV causes over 500,000 cases of cer-
vical cancer annually [5]. Chlamydia and gonorrhea are important
causes of pelvic inﬂammatory disease (PID) in women, which can
lead to infertility, ectopic pregnancy and chronic pelvic pain [6,7].
In addition, several STIs lead to an increased risk of acquiring or
transmitting HIV. HSV-2 infection increases the risk of HIV acqui-
sition by three-fold [8]. Not to be forgotten, the genital symptoms
and psychosocial consequences of STIs have important effects on
quality of life.
ss article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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Fig. 1. Global and regional estimates of the number of new cases of 4 curable STIs (chlamydia, gonorrhea, syphilis, and trichomoniasis) among 15-49 year-olds in 2012.
Global  total = 357 million incident infections [1].
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Sig. 2. Global and regional estimates of the number of prevalent cases of HSV-2 infe
Current STI control is challenged by several factors [9]. First,
lthough condoms are an important STI prevention tool, there have
een limits to progress made with condoms as the main primary
revention measure. Second, most STIs are asymptomatic, and
vailability of affordable, feasible and rapid tests is lacking in many
ettings. Especially in lower-income countries, most infections are
ot diagnosed. Chlamydia screening programs for young women
ave been difﬁcult to bring to scale in high-income countries
nd by themselves, without a strong focus on partner treatment,
ave not resulted in clear reductions in sexual transmission of
hlamydia infections [10]. Third, the growing threat of antimicro-
ial resistance, with increasing reports of cephalosporin-resistant
onorrhea, creates an urgent need for new prevention tools [11].
upply chain shortages of antibiotics, e.g., benzathine penicillin among 15–49 year-olds in 2012. Global total = 417 million prevalent infections [2].
for syphilis, are also a major concern. Finally, STIs are often
stigmatizing and have received little public policy attention. With-
out a simple, clearly effective intervention, it has been difﬁcult to
garner support [9,12]. Thus, while efforts to scale up existing inter-
ventions continue, these challenges highlight the need for ongoing
work toward STI vaccine development.
2. STI vaccine roadmap
In 2013, WHO  and the National Institutes of Health (NIH) orga-
nized a technical consultation to evaluate how to advance STI
vaccine development. The consultation resulted in a special issue
of the journal Vaccine in 2014, which included articles on the
prospects for new vaccines against HSV, chlamydia, gonorrhea,
S.L. Gottlieb et al. / Vaccine 34 (2016) 2939–2947 2941
Table  1
STI vaccine roadmap: nine priority action areas.
1. Obtain better epidemiologic data on STI burden 6. Deﬁne preferred product characteristics for 1st generation vaccines
2.  Improve understanding of STI natural history and sequelae 7. Expedite clinical development and evaluation
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c3.  Model the theoretical impact and cost-effectiveness of STI vaccines 
4.  Advance basic science research for STI vaccines 
5.  Conduct basic and translational studies in human clinical settings as soon as po
yphilis, and trichomoniasis [13]. The special issue concluded with
 proposed global roadmap for STI vaccine development [14]. The
oadmap was developed by consensus, based on discussions at the
echnical consultation, and outlines critical next steps from pre-
accine development through vaccine introduction.
Vaccine development is a long, expensive and risky process,
hich progresses along a deﬁned development pathway [15]. In
he discovery stage, basic science research aims to understand the
isease and protective immune mechanisms in order to select a
andidate vaccine. Typically, preclinical studies in animal models
valuate these candidates. Clinical development involves human
tudies. Small Phase I studies evaluate safety, while slightly larger
hase II trials further characterize safety, immunogenicity, for-
ulations and doses. Phase III studies evaluate vaccine efﬁcacy
nd safety in large randomized, placebo-controlled trials. Success-
ul vaccines then need regulatory approval. At each stage, several
go”/“no go” decisions determine whether the process moves for-
ard, particularly in early development as a candidate is optimized
efore commitment to expensive Phase III trials. “Push” forces,
uch as advances in technology or an inﬂux of funding, and “pull”
orces, such as a clearly deﬁned disease burden or strong market
or the vaccine, can help accelerate vaccine development through
he stages.
The STI vaccine roadmap outlines 9 priority action areas, with
peciﬁc action steps, that can generate push and pull forces and cat-
lyze steps in between, to advance vaccine development (Table 1).
his article presents an overview of key overarching activities
ndertaken to date to advance the STI vaccine roadmap in the fol-
owing areas: obtaining better epidemiologic data, modeling the
mpact of STI vaccines, advancing basic science research, deﬁning
referred product characteristics, and encouraging investment in
TI vaccine development. We  then provide updates on develop-
ent of individual STI vaccines.
. Overarching advances in implementing the STI vaccine
oadmap
.1. Obtaining better epidemiologic data on STI burden
One of the key action items in this area of the roadmap was  to
pdate global and regional estimates of STI burden. In 2015, WHO
pdated estimates of the global prevalence and incidence of HSV-2
nfection [2], and released the ﬁrst-ever global estimates of HSV-1
nfection [3]. An estimated 417 million people aged 15–49 years
ad HSV-2 infection (11.3% prevalence) in 2012 [2]. HSV-1 infec-
ion affected an estimated 3.7 billion people aged 0–49 years (67%
revalence), of whom an estimated 140 million people had HSV-
 genital infection [3]. Thus, more than 500 million people aged
5–49 years had genital infection with either HSV-1 or HSV-2 [2,3].
hese ﬁgures are currently being used to generate estimates of the
urden of neonatal herpes infections, expected in 2016.
HSV-2 infection was also added to conditions evaluated in the
lobal Burden of Disease (GBD) Study 2013, which estimated that
SV-2 infection resulted in 311,600 years lived with disability
YLD) in 2013 from genital ulcer disease alone [16]. These YLD
stimates do not include disability due to neonatal herpes nor
SV-associated HIV acquisition, which are the most devastating
onsequences of infection. The GBD study has ongoing updates,8. Plan for vaccine introduction in advance
9. Encourage investment in STI vaccine development
which will continue to reﬁne the methodology for evaluating YLD
associated with HSV, including consideration of adding HSV as a
risk factor for HIV.
Updated curable STI estimates were also published in 2015
[1]. In 2012, there were an estimated 131 million new chlamydia
infections, 78 million new gonorrhea infections, 5.6 million new
syphilis infections and 143 million new trichomoniasis infections
[1]. The GBD 2013 study demonstrated that although syphilis had
the fewest number of cases, its associated fetal and neonatal com-
plications meant syphilis had the highest disability-adjusted life
years lost of all the curable STIs [17]. In many regions, and espe-
cially for men, these STI estimates were constrained by a paucity
of published prevalence data. Following a consultation meeting in
2015, WHO  is pursuing strategies to strengthen country-level STI
surveillance and improve the methodology for future estimates.
Improved global data on the burden of PID and infertility related to
chlamydia and gonorrhea will also be important.
As de novo dedicated STI burden studies may  be too resource-
intensive and not realistic in many settings, another roadmap
recommendation was to partner with research sites to leverage
existing but non-published STI data. One such project that has
emerged from these discussions is STIMA, an STI individual partic-
ipant data meta-analysis using combined data from 18 prospective
HIV prevention studies, which were initially combined to look at
the effect of hormonal contraception on HIV acquisition [18]. These
data represent over 37,000 women in sub-Saharan Africa, more
than 95% of whom have data with which STI prevalence or incidence
can be assessed. In the future, in addition to newer HIV preven-
tion trials, it will be important to consider evaluating STI data from
HPV vaccine, circumcision, and contraception trials. It will also be
important to continue to seek opportunities to add STI variables
to surveillance studies and clinical and prevention trials, especially
from the outset.
3.2. Modeling the theoretical impact of STI vaccines
An HSV vaccine modeling meeting was held at WHO  in March
2015 to review existing models and identify modeling needs related
to HSV infection, costs and the theoretical impact of an HSV vac-
cine. Several existing models showed that even an imperfect HSV
vaccine could be beneﬁcial [19–21]. However, the group outlined
several new modeling needs critical to advancing HSV vaccine
development and decision-making in the future, such as inclusion
of HSV-associated HIV incidence and neonatal herpes as model out-
comes and incorporation of HSV-1 infection, both as an outcome
and as a potential modiﬁer of the impact on HSV-2. The group also
recommended modeling in different epidemiologic and economic
settings, and inclusion of cost-effectiveness analyses. In order to
conduct these models, better primary data from low- and middle-
income countries (LMICs) on neonatal herpes and on the costs of
HSV will be crucial. The planned Child Health and Mortality Pre-
vention Surveillance (CHAMPS) network [22], which will explore
the causes of neonatal deaths in developing countries, may  allow
collection of much needed data on fatal neonatal HSV infections.New chlamydia vaccine modeling efforts in 2015 include work
suggesting that a successful chlamydia vaccine could be cost-
effective [23]. Although there are many unknowns related to
chlamydial vaccine development, these kinds of exercises lay the
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ramework for thinking through pertinent assumptions and model
tructure, and can be updated as vaccine development advances.
.3. Advancing basic science research
The US National Institute of Allergy and Infectious Diseases
NIAID), part of the NIH, has held several workshops focused on
dvancing basic science for STI vaccine development. The report
f a workshop for HSV vaccine development was  published in
he special issue of the journal Vaccine in 2014 [24]. Workshops
ere also held to focus on gaps and challenges for the develop-
ent of chlamydia and gonorrhea vaccines. In May  2015, chlamydia
esearchers from around the world gathered to discuss the status
f chlamydia vaccine development, gaps in current knowledge of
mmune responses and in correlates of protective immunity, the
otential beneﬁts of an effective chlamydia vaccine, and issues per-
aining to clinical testing of vaccine candidates. A similar meeting
as held in June 2015 to discuss a vaccine to prevent gonococcal
nfection. Reports from both workshops will be released in 2016.
One of the goals of these workshops was to identify potential
eagents, immunogens, and assays that, if standardized and made
vailable to researchers, might accelerate moving vaccine candi-
ates from animal studies into clinical evaluation. To facilitate this
rocess, NIAID offers targeted product development support to
ssist in identifying and ﬁlling critical gaps in the product devel-
pment pipeline.
.4. Deﬁning preferred product characteristics
Preferred product characteristics (PPCs) reﬂect formal WHO
uidance on the desired parameters of a vaccine that would meet
riority public health goals, especially for LMICs [25]. A PPC doc-
ment describes characteristics such as vaccine indications, target
roups, possible immunization strategies, and desired clinical trial
ata related to safety and efﬁcacy, e.g., whether the endpoint is pre-
ention of morbidity or infection, or the efﬁcacy requirements to
chieve a minimum public health effect [26]. PPCs are intended to
rovide early guidance to any entity intending to eventually seek
HO  vaccine prequaliﬁcation and policy recommendations, and
ay  be distinguished from industry-generated target product pro-
les in that they are tailored speciﬁcally to the needs of LMICs. PPCs
re derived through a stakeholder consultation process that estab-
ishes a shared global vision and are generated for vaccines that
HO  considers a public health priority. Thus, they engage regula-
ors and policy-makers early on and can catalyze industry support
nd shape target product proﬁles used by industry and by some
unding entities.The Product Development for Vaccines Advisory Committee
PD-VAC) provides strategic advice to WHO  related to vaccines in
arly clinical development, and makes recommendations related
o developing PPCs for a particular vaccine. HSV vaccines weress case. PPCs = preferred product characteristics.
reviewed at the 2015 PD-VAC meeting (background paper by John-
ston et al. [27]). Because of the global immunization focus on
preventing deaths in children under 5 years, PD-VAC recommended
studies to obtain better data on neonatal herpes in LMICs, in par-
ticular through the CHAMPS evaluation. Because HSV-2 infection is
associated with an increased risk of HIV infection, with an esti-
mated population attributable risk percentage of 48% in some
populations [28], the committee encouraged modeling studies to
evaluate the potential for HSV vaccines to reduce HIV infection
rates. Finally, PD-VAC supported the development of a robust
investment case, including assessment of potential vaccine impact
on a broad array of HSV-2 and HSV-1 outcomes, in order to catalyze
further HSV vaccine research and development.
3.5. Encouraging investment in STI vaccine development
In line with the STI vaccine roadmap and PD-VAC recommenda-
tions, WHO  aims to generate a comprehensive business case for
HSV vaccine development to outline the public health rationale
for the vaccine. The business case ﬁrst demonstrates the public
health need for the vaccine in terms of the disease burden and
costs (Fig. 3). This helps determine the market for the vaccine,
within the context of competing interventions, and allows mod-
eling of potential vaccine impact and cost-effectiveness. Outlining
disease burden epidemiology and modeling vaccine impact also
facilitate deﬁning preferred product characteristics. These PPCs,
along with basic science and technology, determine the precise
vaccine development pathway and costs. The balance of the pro-
jected market demand and vaccine impact with the projected costs
of vaccine development determines the potential return on invest-
ment. Once available, the business case document will help inform
decision-making and rationalize investment by varied stakehol-
ders, including donors, vaccine developers and manufacturers, and
policymakers. To date, a detailed work plan and budget for an
HSV vaccine business case has been developed. Business cases for
chlamydia, followed by other STI vaccines, will also be instructive
as development of these vaccines advances.
Raising awareness about STI vaccine development is also critical
for encouraging investment. Since development of the STI vac-
cine roadmap, the global introduction of HPV vaccine, including in
LMICs, has produced widespread recognition that STI vaccines can
be successfully introduced. The global need for development of STI
vaccines has also been highlighted in a number of academic forums,
such as the Global Vaccine and Immunisation Research Forum and
the World STI and HIV Congress.
4. Progress in research and development of individual STI
vaccines
The current status of the development pathway for STI vaccines
is shown in Fig. 4. Vaccine development efforts are furthest along for
S.L. Gottlieb et al. / Vaccine 34 (2016) 2939–2947 2943
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rFig. 4. Current status of the de
SV, for which several vaccine candidates are in Phase I and II trials.
rogress has been made in the preclinical development of chlamy-
ia vaccine candidates, with the ﬁrst Phase I clinical trials expected
o start in 2016. Vaccine development is not as advanced along the
evelopment pathway for gonorrhea and syphilis, but candidates
re emerging that could be developed over the next several years.
pdates on the progress in research and development for these four
accines follow. The path to vaccine development for trichomonia-
is is the least understood, with more basic science research needed,
s well as better epidemiologic and natural history data.
.1. Herpes simplex virus
The STI vaccine roadmap catalyzed the HSV vaccine ﬁeld in
everal important ways. In addition to the new global estimates
f HSV-1 and HSV-2 infection demonstrating the high burden of
SV infection worldwide, the roadmap also stimulated discussion
bout the PPCs of an HSV vaccine. A prophylactic vaccine to pre-
ent genital HSV infection, which would be effective in both HSV-1
eropositive and seronegative persons and could be given either as
art of the adolescent or childhood platform, would be ideal. The
ost recent prophylactic Phase III HSV vaccine trial tested a subunit
lycoprotein D2 vaccine to prevent symptomatic genital herpes dis-
ase in 8323 North American HSV-1/HSV-2 seronegative women
29]. The vaccine demonstrated efﬁcacy of only 20% against genital
erpes disease, which did not justify continued development of this
andidate. However, several important ﬁndings emerged from this
andmark trial. Surprisingly, the overall attack rate for symptomatic
enital HSV disease was only 1.1% [29], suggesting that future trials
hould consider either an alternative endpoint, such as HSV infec-
ion, or be conducted in individuals at greater risk of genital HSV
isease. Furthermore, of the 183 women in the trial who  became
nfected with HSV, only 62 (34%) had symptomatic or suspected
enital disease and 121 (66%) acquired HSV-1, demonstrating the
mportance of both asymptomatic infection and the emerging role
f genital HSV-1 [30]. Finally, higher antibody titers to gD-2 were
ssociated with increased vaccine efﬁcacy against HSV-1 infection
nd disease, suggesting the ﬁrst immune correlate of protection
gainst HSV [31]. The results from this trial will be instrumental
n deﬁning PPCs and designing future prophylactic HSV vaccine
rials.
Despite the disappointing efﬁcacy results of the Phase III trial,
he HSV vaccine ﬁeld remains very active. Five vaccine candidates
ave entered Phase I/II testing over the past two years, and numer-
us other candidates are in development. These vaccine candidates
re reviewed in more detail in the HSV vaccine development brief
y Johnston et al. [27]. Four vaccine candidates being evaluated
n early clinical studies use novel epitope/adjuvant combinations,
nd one candidate in Phase I studies, HSV529, is a live, replication-
efective HSV-2 vaccine candidate with deletions in UL5 and UL29
32]. Most of the vaccines in clinical trials are currently being
ested in persons with HSV-2 infection to reduce genital herpes
ecurrences and shedding (“therapeutic vaccination”) rather thanment pathway of STI vaccines.
to prevent infection among HSV seronegative individuals. These
early phase studies of therapeutic HSV vaccines are using a reduc-
tion in the frequency of genital HSV shedding as the primary clinical
endpoint, rather than time to ﬁrst genital herpes recurrence, which
has been used in previous studies [33]. Because HSV shedding is in
the causal pathway for HSV recurrences, it is an excellent biomarker
for HSV disease severity [34].
Promising preliminary results from the Phase II trial of the
GEN-003 therapeutic vaccine, a protein subunit vaccine with gD2
and ICP4 and Matrix M2  adjuvant, have shown an approximate
50% decline in the genital HSV shedding rate, with similar interim
results seen in a dose-ﬁnding Phase II trial [35]. A Phase II study of
the HerpV vaccine, a 32-peptide vaccine linked to heat shock pro-
tein and QS-21 adjuvant, showed a 15% decline in HSV shedding
frequency. Results from two DNA vaccines currently in Phase II tri-
als are eagerly awaited [36,37]. Other advances in the ﬁeld include
the increasing number of full-length HSV genomes which have been
sequenced from around the world [38–40]. Sequencing data have
revealed that vaccine candidate glycoprotein D is highly conserved
between HSV-1 and HSV-2 [41]. Data showing that gD and gB stim-
ulate the dominant neutralizing antibody response to HSV, as well
as greater understanding of the importance of type-speciﬁc neu-
tralizing antibody responses to HSV infection will guide vaccine
development [42]. In addition, recently identiﬁed tissue resident
memory CD8+ T-cells may  be important to stimulate, for both pro-
phylactic and therapeutic vaccination [43]. The recent momentum
in the HSV vaccine ﬁeld lays the groundwork for novel approaches
to HSV vaccine design and provides hope that effective HSV vac-
cines may  be developed in the near future.
4.2. C. trachomatis
The prospects for a C. trachomatis vaccine are increasingly
promising, primarily because the last 3 years has seen the rapid
development of new tools for Chlamydia research that will acceler-
ate vaccine development. One of the major developments has been
the long-awaited technology to genetically manipulate Chlamydia
[44]. By paying careful attention to detail, it is possible to cure C. tra-
chomatis of its native plasmid and then to engineer the plasmid to
contain an Escherichia coli origin and subsequently re-introduce the
plasmid with a testable foreign gene. An important complementing
strategy has been the production of mutant libraries. At this time,
these libraries are not usually isogenic (i.e., only contain changes
in a single gene). Nevertheless, because it is relatively inexpensive
to sequence cloned isolates from such libraries, and these cloned
mutant strains can be tested both in vitro and in vivo, several groups
are now making use of this technology to identify and characterize
novel virulence genes [45–48]. One laboratory has tested each of the
open reading frames of the chlamydial plasmid and has identiﬁed
key roles for pgp3 and pgp4 [45,49]. Another has used this strat-
egy to analyze an increasing number of key chlamydial proteins
[46–48]. Together, these approaches are facilitating identiﬁcation
and validation of novel vaccine targets.
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While the Chlamydia muridarum mouse model has long been
sed by chlamydiologists for both basic science and vaccine
evelopment, it is widely acknowledged to have several short-
omings. Work has therefore continued to utilize the non-human
rimate model and this has enabled testing of an attenuated
lasmid-free chlamydial strain as a potential trachoma vaccine
50]. Overall the results are quite promising, with the plasmid-free
train of C. trachomatis producing very mild eye infections and pro-
iding signiﬁcant protection against wild type challenge. There is a
ord of warning as subtle differences in the ocular versus genital
ract sites may  result in unexpectedly different outcomes [51]. A
ovel mini-pig model has allowed evaluation of a multi-subunit
ajor outer membrane protein (MOMP)-derived vaccine candi-
ate against sexually transmitted chlamydial infections, which was
ighly immunogenic and offered promising levels of protection
gainst vaginal C. trachomatis infection in immunized pigs [52].
 ﬁrst-generation vaccine candidate based on this technology is
cheduled to enter phase I clinical trials in 2016 [53].
A key aspect of any vaccine work is to develop correlates of pro-
ection and to better understand the mechanisms of immunity. A
ey publication in 2015 showed that by utilizing novel adjuvant-
ntigen strategies (charge-switching synthetic adjuvant particles),
t was possible, using the mouse model, to not only stimulate a
trong CD4 response to chlamydial infection, but also to direct
t to the genital mucosa where it is required [54]. For a genital
. trachomatis vaccine to be effective, it will likely need to elicit
issue-resident T cells. While the chlamydial MOMP  has long been
he focus of vaccine development, several new candidate anti-
ens (e.g., polymorphic membrane proteins [PMPs]) are emerging
nd are showing great promise, in both mouse and primate mod-
ls. Combined with the live attenuated vaccine strategy, plus an
xpanding list of novel adjuvants, there is great promise for more
accine candidates to be developed. Overall, new tools and new
iscoveries certainly bring new hope to C. trachomatis STI vaccine
evelopment, and it is likely that several candidate vaccines will
nter Phase I clinical trials in the next few years.
.3. N. gonorrhoeae
Despite the intense innate inﬂammatory response that is the
allmark of N. gonorrhoeae, there is no naturally acquired immu-
ity to the bacteria, making it difﬁcult to predict which type(s)
f response might be protective. Moreover, N. gonorrhoeae is
xquisitely adapted to life in humans, and this host restriction
as hampered efforts to model infection or disease, which would
rovide insight as to how these bacteria persist within the infected
ucosa. While these challenges have hampered progress on vac-
ine development, the urgency associated with emergence of
ultidrug-resistant gonococcal strains has dovetailed with recent
dvances in genomic diversity, modeling infection and our under-
tanding of immunity to re-invigorate the ﬁeld.
Perhaps the single greatest hurdle in the development of a gono-
occal vaccine stems from the host restriction of these bacteria,
hich makes it difﬁcult to establish gonococcal infection in labora-
ory animals. Demonstration that estradiol-treated mice become
olonized with N. gonorrhoeae after vaginal inoculation was a
ajor advance in this regard, providing a model in which candi-
ate vaccines can be tested [55]. Studies using this model have
ecently provided new insight into the immune response to infec-
ion. Speciﬁcally, normal infection elicits an inﬂammatory Th17
esponse that precludes development of adaptive immunity; if
ytokine or other adjuvants are used to skew this to a Th1-based
esponse, mice become immune to repeat infection [56,57]. The
resence of host restrictions also makes it difﬁcult to use animal
odels to appreciate the contribution of virulence factors that
re speciﬁc for humans. Ongoing work to ‘humanize’ mice, such4 (2016) 2939–2947
as by generation of transgenic animals expressing human CEA-
CAM receptors to which gonococci adhere, human transferrin and
lactoferrin that they use for iron, and human-derived complement
regulatory proteins that gonococci use to evade complement-
mediated killing, has provided models of uncomplicated lower
genital tract infection and pelvic inﬂammatory disease that more
closely reﬂect gonococcal infection within the human genital
mucosa. These provide an exciting platform to focus vaccine devel-
opment efforts on targets that provide essential functions, and to
test the potential impact of antigen-speciﬁc immune responses
against these targets.
While more sophisticated mouse models allow systematic eval-
uation of vaccine antigens, adjuvants and immunization routes, and
enable a search for correlates of protection, it is clear that some
aspects of immunity may  differ between mice and humans. This
has motivated efforts to re-establish clinical cohorts to study the
natural history of gonococcal infection [58], provide samples with
which to understand genome [59] and transcriptome [60] diversity
among gonococcal isolates, and to exploit ‘omics’-level approaches
to discriminate between protective and pathogenic host responses.
These studies will undoubtedly provide a richer understanding of
the gonococcal lifestyle and help validate various aspects of the
mouse-based studies. Providing a critical link between these two
approaches has been the recent re-establishment of experimen-
tal human male urethra infection studies at the University of North
Carolina at Chapel Hill [61]. While restricted in its capacity to assess
large numbers of variables, the importance of this model for con-
ﬁrming the contribution of virulence factors or establishing the
efﬁcacy of candidate vaccines cannot be overstated.
The emergence of multidrug-resistant N. gonorrhoeae has led to
a global awareness of the urgent threat presented by this pathogen.
This has prompted genome sequencing-based efforts to under-
stand drug resistance, which provides a population-level view of
gonococcal genetic diversity that allows the variability of puta-
tive vaccine targets to be appreciated. This new understanding is
emerging in parallel with the sophistication of preclinical mouse,
experimental human and population-based studies of gonococcal
infection. Momentum in each of these endeavors has led gonococcal
investigators to aim to integrate the varied efforts being undertaken
to develop new vaccines, and to develop a pipeline of candidates
to expedite the path into clinical trials and support the goal of
delivering an effective gonococcal vaccine.
4.4. T. pallidum
Although some progress has been made in reducing the num-
ber of syphilis infections globally [1], syphilis remains an important
cause of fetal and neonatal mortality in many LMICs [4,62], and out-
breaks have continued to occur in several high-income countries
[63,64], especially among gay, bisexual and other men who  have
sex with men  who are often co-infected with HIV [65]. The ongoing
threat posed by syphilis highlights the crucial need for continu-
ing work to develop an effective syphilis vaccine. However, only a
limited number of investigators worldwide work on syphilis vac-
cine development. One body of research primarily focuses upon
deciphering the complexities associated with the process of anti-
genic variation within T. pallidum and establishment of persistent
and recurrent infection [66–69]. Another focuses upon trepone-
mal  dissemination within the host [70–73]. The goal of both
areas of research is to use a reverse vaccinology approach, com-
bined with targeted functional studies, to fully understand critical
host–pathogen interactions and key pathogenic mechanisms uti-
lized by T. pallidum, at least some of which appear to be novel and
exquisitely tailored for the requirements of an obligate pathogen.
Information from these studies is then used to identify optimal
syphilis vaccine targets.
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The major advance in syphilis vaccine development over the last
wo years has been the commitment by investigators to join forces
nd propose a two-pronged approach to prevention of syphilis
nfection, whereby a vaccine cocktail of antigens critical for chan-
re development [66–69] are combined with an antigen essential
or treponemal dissemination [70–72]. Such an approach, if suc-
essful, would deliver a “holistic” vaccine that stems transmission
f syphilis during the primary stage of infection via prevention
f ulcerative chancres, and simultaneously prevents the serious
equelae (congenital infection, neurosyphilis) and secondary stage
ransmission that occur due to treponemal dissemination.
A path moving forward for syphilis vaccine development is
ital to evaluate the currently available vaccine approach and to
ttract new investigators to the ﬁeld to develop additional vac-
ine targets and strategies. Advances in sequencing of circulating
yphilis strains can provide additional information on the cross-
rotective potential of selected vaccine targets [74,75]. Ongoing
tudies investigating immune correlates associated with protec-
ion from disease, adjuvant optimization to achieve these immune
unctions, and mathematical modeling studies to predict the global
ealth impact of a syphilis vaccine will also be valuable. Widespread
upport and innovative partnerships will be needed to catalyze
yphilis vaccine development and combat a global disease that
as devastating consequences for reproductive and fetal/newborn
ealth, affecting the general population of many LMICs and key
opulations worldwide.
. Moving forward
The STI vaccine roadmap outlines priority action steps to
dvance STI vaccine development. Since its publication, much
rogress has been made in several overarching activities to obtain
etter epidemiologic data to establish the public health rationale
nd global market for these vaccines, to model the theoretical
mpact of future vaccines, and to establish what is needed to
eﬁne preferred product characteristics and encourage investment
n STI vaccine development. Several basic science advances for
ndividual vaccines have beneﬁted from parallel efforts to coor-
inate and streamline research and product development among
nvestigators. The greatest advances have been made with HSV vac-
ine development, where multiple promising vaccine candidates in
arly clinical trials provide hope that an HSV vaccine is on the hori-
on. However, the ﬁrst new sexually transmitted chlamydia vaccine
andidate will be entering phase I trials, and new technology
dvances will see several more vaccine candidates in the pipeline.
A conﬂuence of factors, such as international roll-out of HPV
accine raising global awareness of a successful STI vaccine, the
rowing specter of multidrug-resistant gonorrhea, technological
dvances in antigen selection and novel adjuvants, and the STI
accine roadmap itself, has provided renewed enthusiasm for
TI vaccine development. Interest in STI vaccine development
as dovetailed with the growing movement around develop-
ent of multipurpose prevention technologies, which combine
arious HIV, STI and pregnancy prevention features [76]. Both
fforts heighten awareness of the importance of harnessing new
echnology advances to improve sexual and reproductive health
orldwide. In order to capitalize on this momentum, the goal is
o expand on the substantial collaborative efforts already under-
aken by the STI vaccine community to develop an overarching STI
accine consortium, with working groups for each STI. The STI vac-
ine roadmap provides a framework to coordinate and streamline
ctivities so that they contribute to a larger cohesive whole. HSV
accine has been prioritized in initial efforts, in terms of conducting
mpact modeling, generating PPCs, and developing a business case,
s its research and development program is furthest along. These4 (2016) 2939–2947 2945
types of activities are now needed for chlamydia and gonorrhea
vaccines as well, along with redoubled efforts to jumpstart syphilis
vaccine development. With continued support and collaboration,
these much needed STI vaccines can be made a reality.
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